Azstarys generic
Azstarys is an ADHD medication developed and owned by Commave Therap. It's composed of two active ingredients: Dexmethylphenidate Hydrochloride and Serdexmethylphenidate Chloride. The drug, available in oral capsules, was first approved for market usage on 7th May, 2021. So far, Azstarys has received a total of 6 patents, none of which have yet expired.
When will Azstarys generic be available?
The expectation for Azstarys' generic release is set for anytime after 9th December, 2037. This is based on the expiration of the last-standing patent, US10584113 titled 'Methylphenidate-prodrugs, processes of making and using the same', which is set to expire on the same date. Drug patent challenges for Azstarys may begin from 7th May, 2025.
Azstarys uses
Azstarys is primarily used in the treatment of attention-deficit hyperactivity disorder (ADHD). Its effectiveness lies in its two active ingredients. Dexmethylphenidate Hydrochloride is a stimulant that enhances focus and reduces impulsive behavior. On the other hand, Serdexmethylphenidate Chloride works as a prodrug, converted by the body into the active drug dexmethylphenidate, thereby prolonging the effects of the medication.
Azstarys patent expiration
Azstarys currently enjoys patent protection through six patents. One of the most significant of these is patent US10584113 with the title 'Methylphenidate-prodrugs, processes of making and using the same', which will expire on 9th December, 2037. This patent's expiration will essentially pave the way for the release of Azstarys generics. Below are the details of the patents: